STOCK EXCHANGE RELEASE - OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE
Recommendation by the Orion Nomination Committee on the proposals to be submitted to the 2024 Annual General Meeting
Recommendation on the number of members of the Board of Directors and its composition
The number of Board members would be eight.
Of the present members of the Board,
Of the present members,
The members of the Nomination Committee say: "We would like to take this opportunity to express our warmest thanks to
Personal information of
Born: 1967
Education and profession:
Essential work experience:
- Swedish Orphan Biovitrum AB, CFO, 2018–
- Recipharm AB, CFO, 2017–2018
Meda AB , CFO, 2003–2017
Current key positions of trust:
Member of the Board:
Former key positions of trust:
Member of the Board: MedCap AB 2017–2019
Presentations of current Board Members are available on Orion's website: https://www.orion.fi/en/investors/corporate-governance/board-of-directors/
Recommendation on remuneration to be paid to members of the Board of Directors
In addition, the Nomination Committee announces as its recommendation that the following remunerations would be paid to the Board of Directors:
As an annual fee, the Chairman would receive
In addition, as a fee for each meeting attended, the Chairman would receive
Of the above-mentioned annual fees, 60 percent would be paid in cash and 40 percent in Orion Corporation B shares, which would be acquired for the members over the period 26 April–3 May 2024 from the stock exchange in amounts corresponding to
In addition, the company would pay the transfer tax related to the part of the annual fee of the Board of Directors paid in shares.
Potential statutory social security and pension costs incurring to Board members having permanent residence outside
Board members would be required to retain ownership of the Orion Corporation B shares paid as fees for a period of two years from the date of payment of the fees. However, if the person's membership of the Board of Directors of the company were to end before the expiry of the restriction on transfer, the restriction on transfer would expire at the end of the membership of the Board of Directors.
The Nomination Committee has not given its recommendation for the remunerations to the Board of Directors, but the matter will be proposed by a shareholder at the AGM.
The Nomination Committee notes that the fees are the same as those decided in 2023.
The members of the Nomination Committee belonging to the Board of Directors did not participate in the consideration or decision-making of the recommendation on the remuneration of the Board of Directors.
The Nomination Committee has consisted of the following members:
President and CEO | SVP, Corporate Functions |
Contact person:
Tel. +358 50 1537
Publisher:
Communications
Orionintie 1A, FI-02200
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to
Attachment
- PHOTO:
Henrik Stenqvist
© OMX, source